Cover Image
市場調查報告書

腹部主動脈血管瘤:開發平台分析

Abdominal Aortic Aneurysms - Pipeline Review, H1 2015

出版商 Global Markets Direct 商品編碼 335690
出版日期 內容資訊 英文 49 Pages
訂單完成後即時交付
價格
Back to Top
腹部主動脈血管瘤:開發平台分析 Abdominal Aortic Aneurysms - Pipeline Review, H1 2015
出版日期: 2015年06月17日 內容資訊: 英文 49 Pages
簡介

被稱為AAA的腹部主動脈血管瘤是指血管部分肥厚或薄化造成血管比正常直徑擴張50%以上的狀態。症狀有背部或腹部持續性疼痛、發汗、冷汗、心搏過速、失神或頭暈等。發病要素有年齡、動脈粥狀硬化性心血管疾病、抽煙、家族病史等。

本報告提供腹部主動脈血管瘤的治療藥開發情形調查分析,提供您開發中的產品概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等相關的系統性資訊。

目錄

簡介

腹部主動脈血管瘤概要

治療藥的開發

  • 開發中產品:概要
  • 開發中產品:比較分析

開發中的治療藥:各企業

開發中產品的概要

  • 臨床階段的產品
  • 初期階段的產品
  • 開發階段不明的產品

開發中的產品:各企業

調查中的產品:大學/研究機關別

開發治療藥的企業

  • AstraZeneca Plc
  • Carolus Therapeutics, Inc.
  • Eli Lilly and Company
  • Novartis AG

治療藥的評估

  • 單獨療法的情況
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • BSN-908
  • canakinumab
  • CT-2009
  • LY-3000328
  • ticagrelor

開發中產品的最新趨勢

暫停的計劃

附錄

圖表

目錄
Product Code: GMDHC6800IDB

Summary

Global Markets Direct's, 'Abdominal Aortic Aneurysms - Pipeline Review, H1 2015', provides an overview of the Abdominal Aortic Aneurysms's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Abdominal Aortic Aneurysms, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Abdominal Aortic Aneurysms and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Abdominal Aortic Aneurysms
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Abdominal Aortic Aneurysms and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Abdominal Aortic Aneurysms products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Abdominal Aortic Aneurysms pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Abdominal Aortic Aneurysms
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Abdominal Aortic Aneurysms pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Abdominal Aortic Aneurysms Overview
  • Therapeutics Development
    • Pipeline Products for Abdominal Aortic Aneurysms - Overview
    • Pipeline Products for Abdominal Aortic Aneurysms - Comparative Analysis
  • Abdominal Aortic Aneurysms - Therapeutics under Development by Companies
  • Abdominal Aortic Aneurysms - Pipeline Products Glance
    • Clinical Stage Products
    • Early Stage Products
    • Unknown Stage Products
  • Abdominal Aortic Aneurysms - Products under Development by Companies
  • Abdominal Aortic Aneurysms - Companies Involved in Therapeutics Development
    • AstraZeneca Plc
    • Carolus Therapeutics, Inc.
    • Eli Lilly and Company
    • Novartis AG
  • Abdominal Aortic Aneurysms - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • BSN-908 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • canakinumab - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CT-2009 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • LY-3000328 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ticagrelor - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Abdominal Aortic Aneurysms - Recent Pipeline Updates
  • Abdominal Aortic Aneurysms - Dormant Projects
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Abdominal Aortic Aneurysms, H1 2015
  • Number of Products under Development for Abdominal Aortic Aneurysms - Comparative Analysis, H1 2015
  • Number of Products under Development by Companies, H1 2015
  • Comparative Analysis by Clinical Stage Development, H1 2015
  • Comparative Analysis by Early Stage Development, H1 2015
  • Comparative Analysis by Unknown Stage Development, H1 2015
  • Products under Development by Companies, H1 2015
  • Abdominal Aortic Aneurysms - Pipeline by AstraZeneca Plc, H1 2015
  • Abdominal Aortic Aneurysms - Pipeline by Carolus Therapeutics, Inc., H1 2015
  • Abdominal Aortic Aneurysms - Pipeline by Eli Lilly and Company, H1 2015
  • Abdominal Aortic Aneurysms - Pipeline by Novartis AG, H1 2015
  • Assessment by Monotherapy Products, H1 2015
  • Number of Products by Stage and Target, H1 2015
  • Number of Products by Stage and Mechanism of Action, H1 2015
  • Number of Products by Stage and Route of Administration, H1 2015
  • Number of Products by Stage and Molecule Type, H1 2015
  • Abdominal Aortic Aneurysms Therapeutics - Recent Pipeline Updates, H1 2015
  • Abdominal Aortic Aneurysms - Dormant Projects, H1 2015

List of Figures

  • Number of Products under Development for Abdominal Aortic Aneurysms, H1 2015
  • Number of Products under Development for Abdominal Aortic Aneurysms - Comparative Analysis, H1 2015
  • Number of Products under Development by Companies, H1 2015
  • Assessment by Monotherapy Products, H1 2015
  • Number of Products by Top 10 Targets, H1 2015
  • Number of Products by Stage and Top 10 Targets, H1 2015
  • Number of Products by Top 10 Mechanism of Actions, H1 2015
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015
  • Number of Products by Top 10 Routes of Administration, H1 2015
  • Number of Products by Stage and Top 10 Routes of Administration, H1 2015
  • Number of Products by Top 10 Molecule Types, H1 2015
  • Number of Products by Stage and Top 10 Molecule Types, H1 2015
Back to Top